PharmaTelevision - Ablynx’s Success Story: The Past, Present and Future

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Ablynx’s Success Story: The Past, Present and Future

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

Fintan Walton talks to Edwin Moses, CEO of Ablynx, about the success that the company has enjoyed since its inception, and his plans for it going forward. Edwin talks about the importance of location in relation to the financing environment, and the difference in the ease of raising cash through an IPO depending upon your location. He also expands upon Ablynx’s commercial strategy in terms of partnering with big pharma, acquiring other technologies, targets and products, and Ablynx’s goal of becoming a fully integrated, independent pharmaceutical company in its own right.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Origins of Ablynx and differences in running a biotech company in 1990's and 2000's.

Fintan Walton:

Welcome to PharmaVentures Business Review brought to you by PharmaTelevision the world's first on demand pharmaceutical television channel. We are here in San Francisco recording a series of interviews at the annual JP Morgan Conference. This conference was originally run by the famous Hambrecht and Quist Bank and is one of the oldest events in biotechnology. Today thousands to send from around the US but also from around the world into San Francisco to do financial deals and recently it's also become an important partnering event. I hope you'll enjoy the series of interviews we've done from some of the key companies attending this conference. Hello and welcome to PharmaVentures Business Review here in San Francisco. On this show I've Edwin Moses, who is Chairman and CEO of Ablynx based in Belgium, welcome to the show.

Edwin Moses:

Thank you.

Fintan Walton:

Edwin Moses, people will know you as the CEO and founder of Oxford Asymmetry, you are more or less a veteran in running biotech companies in Europe, so you've had a lot of experience over the last 15-years at least in taking a leadership role in these sort of companies, so why go for it for a second time with Ablynx ?

Edwin Moses:

I think it's an easy question to answer because I was involved in a lot of biotech companies over the last 15-years and when I got involved in Ablynx as a Chairman and Non-Executive I got to know the company well on the technology and it was probably the most exciting company I have ever come across so it was an opportunity I just couldn't say no to it.

Fintan Walton:

You genuinely mean that?

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Fintan Walton

Dr Fintan Walton is the Founder and CEO of PharmaVentures . After completing his doctoral research on the genetics of cell proliferation at the University of Michigan(US)and Trinity College (Dublin, Ireland), Dr Walton gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992).

Edwin Moses

CEO

Edwin Moses began his commercial career at Amersham International, Enzymatix and Raggio-Italgene. Then, as CEO from 1993 to 2001, and, later, as Chairman, he was responsible for the growth of Oxford Asymmetry through a series of venture rounds, cumulating in a flotation on the London Stock Exchange in 1998, at a value of €175 M (£120 M, US$205); this was followed by the sale of the company to Evotec Biosystems in 2000 for € 460 M (£316 M, US$474.7 M). Over the past 5 years Edwin Moses has sat on the Board (primarily as Chairman) of over 15 European life sciences companies. Edwin Moses has been Chairman of Ablynx since 2004, and, in March 2006, he became Ablynx 's CEO.

PharmaVentures

PharmaVentures is a corporate finance and transactions advisory firm that has served hundreds of clients worldwide in relation to their strategic deal making in the pharmaceutical, life science and healthcare sectors. Our key offerings include: Transactions / deal negotiations; Product / technology valuations; Deal term advice; Due diligence & expert reports; Strategy formulation; Alliance management; and Expert opinion for litigation/arbitration cases. PharmaVentures provides the global expertise to ensure our clients generate the highest possible return on investment from all their deal making activities. We have experience of all therapeutic areas and can offer advice on both product and technology commercialisation.

Ablynx

Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies, a novel class of therapeutic proteins based on single-domain antibody fragments, for the treatment of a range of serious and life-threatening human diseases. The company is developing a portfolio of Nanobody based therapeutic programmes in a number of major disease areas, including inflammation, thrombosis, oncology and Alzheimer's disease. Ablynx has generated nanobodies against more than 100 different disease targets, and has characterized potent antagonists in vitro against 20 different targets.